Camlodin

Quick links to important sections

Camlodin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Camlodin

Quick Facts

Property Description
Active ingredient Amlodipine (besylate)
Form Tablet
Route of administration Oral
Pharmacological class Calcium channel blocker (Dihydropyridine type)
General purpose Antihypertensive and Antianginal agent
Origin Synthetic compound

What Type of Medicine is Camlodin?

Camlodin is a synthetic compound supplied as a single-ingredient product used in the management of cardiovascular conditions. The pharmaceutical preparation is classified as a Calcium channel blocker (CCB), specifically belonging to the Dihydropyridine pharmacological group.

The active ingredient in this medication is Amlodipine, typically administered as Amlodipine besylate. The Dihydropyridine subgroup is designed to be highly selective for relaxing peripheral blood vessels compared to other CCBs, which contributes to its long-acting properties and its use in once-daily dosing. This class is utilized for its ability to regulate vascular smooth muscle contraction, making the oral preparation a foundation for consistent blood pressure management in adult patients.

Composition and General Therapeutic Purpose

The general purpose of Camlodin is to support smoother blood flow by promoting vasodilation, the widening of the arteries. This fundamental physiological action directly reduces the resistance of the blood vessels, effectively lowering elevated blood pressure, classifying the drug as an antihypertensive agent.

This mechanism of vasodilation also enhances oxygen supply to the heart muscle. Amlodipine is used to reduce the load against which the heart works and relieve symptoms associated with an inadequate oxygen supply to the heart, such as stable angina pectoris. A typical use scenario involves stabilizing circulation to maintain normal arterial function.

Camlodin Dosage Form and Origin

Camlodin is presented as a solid-state pharmaceutical preparation in the form of a tablet, intended for the oral route of administration. This standardized oral preparation contains Amlodipine alongside solid excipients required to form the tablet. The synthetic compound origin of Amlodipine provides controlled consistency and purity for therapeutic agents used in monotherapy or combination therapy for chronic cardiovascular disorders.

What side effects are possible with Camlodin?

Possible side effects and safety information

The safety profile of Camlodin (amlodipine) is officially documented by government regulatory agencies, which classify adverse reactions based on their frequency of occurrence and the physiological system affected.

Adverse Reaction Classification

Side effects are categorized by the regulatory frequency framework, which groups effects from Common to Very Rare.

  • Common adverse reactions (ge 1/100 to < 1/10) include peripheral edema (ankle/leg swelling), headache, dizziness, flushing, fatigue, and nausea. Edema is noted in official labels as often being dose-related, meaning its incidence may increase with higher doses.

  • Uncommon reactions (ge 1/1,000 to le 1/100) affect multiple System-Organ Classes, including Nervous System Disorders (such as tremor or hypoesthesia), Gastrointestinal Disorders (like dyspepsia or dry mouth), and Cardiac Disorders (such as arrhythmia).

  • Very Rare reactions (le 1/10,000) include hepatitis, jaundice, and severe skin reactions such as Erythema Multiforme and Stevens-Johnson syndrome.

Serious Safety Considerations

Regulatory documents highlight a risk of serious events, particularly in vulnerable patients. These include a potential for worsening angina or acute myocardial infarction that may occur upon initiating or increasing the dose, especially in patients with severe obstructive coronary artery disease. Other documented serious risks include symptomatic hypotension.

Safety Constraints and Special Populations

Official labels define several situations that act as safety constraints. Contraindications include known hypersensitivity to amlodipine or other dihydropyridines, severe hypotension, and conditions such as cardiogenic shock or obstruction of the outflow-tract of the left ventricle (aortic stenosis). Special cautions are noted for specific populations:

  • Hepatic Impairment: Clearance may be prolonged in patients with liver issues, and severe hepatic impairment is listed as a contraindication in some regulatory documents.
  • Older Adults: Lower initial doses are advised in older adult patients, with careful monitoring upon dose increases.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose is based strictly on descriptions provided in official regulatory documents. An overdose of Camlodin (amlodipine) is expected to result in excessive peripheral vasodilation, leading to marked and probably prolonged systemic hypotension (severely low blood pressure). This severe hypotension may trigger reflex tachycardia, a rapid heart rate, as the body attempts to compensate.

Life-Threatening Manifestations and Emergency Actions

Official labeling indicates that overdosage carries a risk of serious outcomes, including shock and cardiovascular collapse.

Immediate medical help must be sought for any suspected overdose. Emergency medical attention is required if severe symptoms such as fainting (syncope), trouble breathing, seizures, or unresponsiveness occur. In such situations, regulatory guidance mandates immediately calling emergency services (911) and Poison Control.

Officially Documented Management

Management of overdosage centers on providing active cardiovascular support. This may include measures such as elevation of the extremities and fluid administration. If hypotension is unresponsive to these initial steps, the use of a vasoconstrictor is considered. Regulatory documents state that no specific antidote is known for amlodipine. Because of the drug's long half-life, extended clinical monitoring is required following an overdose.

Therapeutic Uses of Camlodin

What Camlodin Treats: Main Uses and Benefits

Camlodin (amlodipine) is generally used in two main therapeutic domains: to address Essential Hypertension and various forms of Angina Pectoris. It is primarily applied across domains where additional symptomatic support is needed for these chronic cardiovascular conditions.


Therapeutic Focus

Camlodin is commonly used to help manage symptoms related to persistently elevated force against artery walls in Essential Hypertension. For patients, the supportive therapeutic approach is considered relevant for easing challenging manifestations that may interfere with functional stability. It is also applied in addressing Myocardial Ischemia Symptoms that create noticeable physiological strain, including Chronic Stable Angina and Vasospastic Angina.


Patient Benefits and Indications

The medication is commonly used to help with conditions presenting with systemic or localized discomfort, including Essential Hypertension in adults and relevant pediatric groups, Chronic Stable Angina, and Vasospastic Angina. For those with documented Coronary Artery Disease, it is considered relevant to support functional stability and contribute to easing the overall symptom load.

Quick Fact: Supportive Management for Cardiovascular Symptoms Camlodin helps ease symptoms related to physical discomfort by supporting the patient during difficult episodes and assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Camlodin (amlodipine) eligibility is strictly defined by regulatory health authorities and centers on age, co-existing medical conditions, and hypersensitivity status. The official label dictates who is allowed to use the medicine and who is absolutely prohibited.

Eligibility Scope

Category Official Regulatory Status
Populations Contraindicated Patients with known sensitivity to the drug, Dihydropyridine derivatives, or excipients. Contraindicated in patients with severe hypotension, shock, outflow tract obstruction (e.g., severe aortic stenosis), or unstable heart failure after acute myocardial infarction.
Age-Related Eligibility Approved for Adult Patients for all labeled uses. Approved for Pediatric Patients (ages 6 to 17) for hypertension only. Safety and effectiveness have not been established in children younger than 6 years of age.
Conditional Use Hepatic Impairment: Use requires caution and slow titration due to the drug’s prolonged half-life in this population. Renal Impairment: No dosage adjustment is required [Source 1.7]. Older Adults: A lower starting dose is often recommended, and dosage increase must be done with care.
Reproductive Status Pregnancy: Use is advised only if the potential benefit justifies the potential risk. Lactation: Official labeling recommends discontinuing nursing when taking the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amlodipine's official interaction profile is defined by pharmacokinetic (metabolic) and pharmacodynamic (additive effects) mechanisms documented in regulatory sources.

Pharmacokinetic Interactions and Exposure Risk

Amlodipine is primarily metabolized by the CYP3A4 enzyme system. Co-administration with strong or moderate CYP3A4 inhibitors (such as clarithromycin, ketoconazole, or diltiazem) is documented to increase the systemic exposure and plasma concentration of amlodipine. Conversely, the use of CYP3A4 inducers, including the herbal product St. John's Wort, may lead to a decrease in amlodipine plasma levels.

Amlodipine also increases the exposure of certain co-administered medicines, including the immunosuppressants Cyclosporine and Tacrolimus. Due to the significantly increased exposure of Simvastatin, regulatory documents mandate a co-administration dose limit of 20 mg daily for this HMG-CoA reductase inhibitor.

Pharmacodynamic Effects and Special Considerations

Combining amlodipine with other antihypertensive agents (e.g., beta-blockers or diuretics) or PDE5 inhibitors may produce an additive blood pressure-lowering effect. Finally, the regulatory profile notes that clearance is significantly impaired in individuals with severe hepatic impairment, resulting in a prolonged half-life and increased systemic exposure, a factor that heightens the relevance of all other drug interactions.

Mechanism of Action

The mechanism of Amlodipine involves the functional blockade of L-type Voltage-Gated Calcium Channels (L-VGCCs), which are expressed predominantly on the membranes of vascular smooth muscle cells. This selective antagonism inhibits the influx of extracellular calcium ions ( Ca^2+) required to facilitate muscle contraction.

By restricting Ca^2+ entry, the drug disrupts the excitation-contraction coupling pathway within the muscle cell. This interruption leads directly to the relaxation of arterial smooth muscle tissue, which is the causal step for vasodilation (widening of the blood vessels) and the subsequent reduction of vascular tension.

This widespread vasodilation decreases Systemic Peripheral Vascular Resistance (afterload). This systemic adjustment lowers the opposition the heart faces when ejecting blood and alters coronary artery tone, influencing blood flow dynamics and oxygen delivery to the myocardium, thereby establishing the final physiological change produced by the mechanism. Amlodipine is characterized by a high selectivity for vascular L-VGCCs, limiting its influence on myocardial contractility.

Dosage and Administration Information

How Camlodin is Used

Camlodin (amlodipine) is intended for long-term oral administration, and its use follows specific guidelines regarding dose, frequency, and timing. The medication is consistently supplied and administered as an oral tablet.

Administration is standardized to a once daily frequency for all approved uses. The drug's long duration of action supports this pattern, which is designed to maintain consistent levels throughout a 24-hour period. Bioavailability is not significantly altered by food, meaning the tablet may be taken with or without food. Maintenance of a consistent time of day for administration is generally recommended to support the daily rhythm of use.

Established Dosing and Titration

Dosage is defined by clinical guidelines regarding initial and maximum amounts. For most adult patients, the standard starting daily dose is 5 mg. The maximum recommended daily dose for all approved indications in adults is 10 mg.

Standard protocols indicate that any adjustment or titration of the dosage should not occur more frequently than every 7 to 14 days. This procedural timeframe allows the drug to reach its full therapeutic concentration (steady-state) before assessment of the physiological response.

Use in Specific Populations

For certain patient groups, the starting dose is lower: a daily dose of 2.5 mg is utilized for small, fragile, or older adults, and for patients with hepatic impairment. In contrast, no dosage adjustment is typically required for patients with renal impairment. For pediatric patients aged 6–17 years, the maximum dose is limited to 5 mg once daily for the management of hypertension.

Recent Clinical Evidence

Research evidence / Overview of studies for Camlodin

Evidence for Use in Essential Hypertension (High Blood Pressure)

Large-scale, formal research, including many randomized controlled trials (RCTs), was studied for its outcomes related to systemic or functional imbalance (high blood pressure). Researchers examined how blood pressure measurements changed in adults with varying levels of hypertension. These studies also monitored the long-term outcomes reflecting daily functioning or activity level and cardiovascular health.

Findings describe patterns observed in the studies where blood pressure levels changed after patients was observed in the research. Specifically, studies reported how symptoms evolved in the observed populations, showing measurements of both systolic and diastolic blood pressure changes. While the evidence contributes to the broader evidence landscape regarding blood pressure changes, long-term effects are not fully established regarding certain sub-groups, and comparative evidence is lacking for some specific combinations of treatment.

Evidence for Use in Chronic Stable Angina

Research was evaluated in adults diagnosed with Chronic Stable Angina, a condition where symptoms may vary in intensity. Trials explored outcomes related to physical discomfort by tracking angina episode frequency using patient diaries. Studies monitored functional capacity through standardized exercise tests to see changes in the time patients could perform exercise before symptoms started.

The data show patterns related to the number of patient-reported episodes of physical discomfort that was monitored. Furthermore, functional tests reported patterns related to symptom-limited exercise duration evaluated in the observed populations. However, the follow-up durations were limited in some trials, meaning there is limited information for long-term outcomes regarding the maintenance of these functional changes.

Evidence in Special Populations and Comorbidities

Research was evaluated in various sub-groups, including older adults and pediatric patients (ages 6–17 years) with high blood pressure. Data showed patterns related to clearance in older adults and those with hepatic impairment (liver function issues); this was observed in some studies. For children, studies monitored changes in blood pressure, although typically at lower doses than those used in adults. Data for certain groups remain insufficient. For instance, evidence is limited regarding the use of higher dose ranges in pediatric patients. Long-term effects are not fully established for individuals with severe liver issues.

Frequently Asked Questions (FAQ)

Common questions about Camlodin (FAQ)


Q: How long does it take for Camlodin to start working to lower blood pressure?

Official product information indicates that the drug's full therapeutic effect is reached when its concentration in the bloodstream becomes consistent (known as steady-state), which is typically after 7 to 8 days of taking the medication once daily. Because Camlodin is intended for long-term management, a healthcare provider may wait up to two weeks before assessing the full impact of a dose adjustment.


Q: Is Camlodin generally considered a safe drug for long-term use?

Yes, regulatory documents confirm that Camlodin is intended for long-term oral administration for chronic conditions. Studies have examined its use in thousands of patients in clinical trials, where it was generally described as well-tolerated at the approved dosages.


Q: Are there any studies looking at Camlodin's use in younger adults?

Official information states that the medicine is approved for use in the adult population, which includes younger adults. Furthermore, clinical trials involving healthy volunteers in the young adult age range (20–32 years) have been conducted to help establish its pharmacokinetic and safety profile.


Q: Does Camlodin affect my sleep or cause insomnia?

According to official regulatory documents, insomnia (difficulty sleeping) is noted as an uncommon side effect. It is important to note that uncommon effects are reported in less than 1 in 100 people taking the medication.


Q: What are the long-term safety concerns noted for Camlodin?

Regulatory documentation outlines certain situations that require careful clinical monitoring during long-term use, particularly for individuals with liver impairment. Rare metabolic side effects, such as changes in blood sugar (hyperglycemia) or weight fluctuation (increase or decrease), have been reported in clinical experience.


Q: Does Camlodin cause weight gain?

Official sources state that both weight increase and weight decrease are noted as uncommon side effects. Uncommon effects occur in less than 1 out of every 100 people.


Q: What happens if I forget to take my daily dose of Camlodin?

Official patient information typically suggests taking the missed dose as soon as remembered. However, if it is almost time for the next scheduled dose, it is typically recommended to skip the missed one. Regulatory guidance advises against taking a double dose to make up for a forgotten one.


Q: Can Camlodin be taken with common pain relievers like ibuprofen?

Official regulatory information indicates that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include medicines like ibuprofen, may reduce the blood pressure-lowering effect of Camlodin. The combination may necessitate increased clinical monitoring.


Q: What should be considered if I stop taking Camlodin?

Regulatory guidance emphasizes that the medication should not be stopped unless specifically instructed to do so by a healthcare provider. Official advice states that the dose may need to be slowly decreased over time when discontinuing the medicine, rather than stopping abruptly.


Q: Is Camlodin an addictive medicine?

Camlodin is not classified as a controlled substance by regulatory health bodies. The active ingredient, amlodipine, is not known to be associated with drug dependence.


Q: How quickly can I stop taking Camlodin once I start?

Regulatory patient information advises that the medicine should be stopped only under the direction of a healthcare provider. The process for stopping the medicine often involves gradually reducing the dose over time.


Q: Does Camlodin affect cholesterol levels or blood sugar?

Hyperglycaemia (high blood sugar) is listed in regulatory documents as a very rare side effect. Clinical data and official summaries have generally shown that Camlodin is not associated with unfavorable changes to cholesterol or triglyceride levels in the body.


Q: Is there a generic version of Camlodin available?

Yes, the active ingredient, amlodipine besylate, is available as a generic drug product.


Q: Will Camlodin change my mood or behavior?

Official documents list certain psychiatric symptoms as possible side effects. Uncommon effects include mood changes, such as anxiety or depression, and confusion is listed as a rare side effect.


Q: Does Camlodin interact with alcohol?

Regulatory information indicates that alcohol may have an additive effect in lowering blood pressure when taken with Camlodin. This combined effect can potentially lead to increased feelings of dizziness or lightheadedness.


Q: Can Camlodin be taken along with common cold or flu medicine?

Caution is advised because many common cold and flu medicines contain ingredients known as sympathomimetic agents. Regulatory warnings advise caution when combining these types of agents with Camlodin, as this combination may cause adverse cardiovascular effects.


Q: Are the original clinical studies on Camlodin based on men or women?

Clinical review documents show that both men and women were included in the studies used for regulatory approval. While some analysis suggests women may reach slightly higher concentrations in the body, the overall reporting of adverse events was similar between the genders.


Q: How do the side effect rates of Camlodin compare to a placebo in clinical trials?

Clinical trial summaries indicate that treatment with Camlodin was associated with a slightly higher incidence of side effects compared to a placebo. This marginal difference was largely attributed to the occurrence of peripheral edema (swelling), which is a common side effect of the medicine.


Q: Do people with diabetes usually take Camlodin?

Regulatory documents do not list diabetes as a condition that prevents the use of Camlodin or requires a specific dose adjustment. However, official information does note that hyperglycemia (high blood sugar) is reported as a very rare side effect.


Q: How does Camlodin compare to other drugs in the same class regarding side effects?

Clinical review summaries indicate that compared to certain other calcium channel blockers, Camlodin may be associated with a higher occurrence of peripheral edema (swelling). Conversely, it is often associated with a lower incidence of other side effects, such as constipation.

How should Camlodin be stored and disposed of?

How to Store and Dispose of Camlodin (Amlodipine Besylate)

The official storage requirements for Camlodin are strictly controlled to maintain product integrity and safety, as defined by regulatory agencies.

Storage Component Official Requirement
Temperature Store at controlled room temperature (typically 15 C to 30 C).
Protection Keep the container tightly closed. Protect the medication from light and moisture; avoid storing in high-humidity areas like a bathroom.
Packaging Must be dispensed and kept in a tight, light-resistant container.
Child Safety Store locked up and out of the reach of children.

Disposal instructions mandate that any unused product or waste material be disposed of in accordance with local, regional, and national regulations. Due to its classification as very toxic to aquatic life, the medication must not be released into the environment, such as through the sewer system or ground.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Camlodin found in:

A-Z Index: